411 related articles for article (PubMed ID: 11438627)
1. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
[TBL] [Abstract][Full Text] [Related]
4. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
[TBL] [Abstract][Full Text] [Related]
5. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
[TBL] [Abstract][Full Text] [Related]
6. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
Graf R; Nyuyki F; Steffen IG; Michel R; Fahdt D; Wust P; Brenner W; Budach V; Wurm R; Plotkin M
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):68-73. PubMed ID: 22575489
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
10. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
Iglseder S; Iglseder A; Beliveau V; Heugenhauser J; Gizewski ER; Kerschbaumer J; Stockhammer G; Uprimny C; Virgolini I; Dudas J; Nevinny-Stickel M; Nowosielski M; Scherfler C
J Neurooncol; 2023 Sep; 164(3):711-720. PubMed ID: 37707754
[TBL] [Abstract][Full Text] [Related]
12. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
13. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT.
Boss A; Bisdas S; Kolb A; Hofmann M; Ernemann U; Claussen CD; Pfannenberg C; Pichler BJ; Reimold M; Stegger L
J Nucl Med; 2010 Aug; 51(8):1198-205. PubMed ID: 20660388
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
15. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [
Milosevic A; Styczen H; Grueneisen J; Li Y; Weber M; Fendler WP; Kirchner J; Damman P; Wrede K; Lazaridis L; Glas M; Guberina M; Eckstein A; Blau T; Herrmann K; Umutlu L; Forsting M; Deuschl C; Schaarschmidt B
J Nucl Med; 2023 Aug; 64(8):1185-1190. PubMed ID: 37385668
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
Thorwarth D; Henke G; Müller AC; Reimold M; Beyer T; Boss A; Kolb A; Pichler B; Pfannenberg C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):277-83. PubMed ID: 21300465
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results.
Afshar-Oromieh A; Wolf MB; Kratochwil C; Giesel FL; Combs SE; Dimitrakopoulou-Strauss A; Gnirs R; Roethke MC; Schlemmer HP; Haberkorn U
Neuro Oncol; 2015 Feb; 17(2):312-9. PubMed ID: 25008094
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging: current status and future perspectives.
Bohuslavizki KH
J Nucl Med; 2001 Jul; 42(7):1057-8. PubMed ID: 11438628
[No Abstract] [Full Text] [Related]
20. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
